Loxo Oncology, Inc.
Clinical trials sponsored by Loxo Oncology, Inc., explained in plain language.
-
New combo aims to keep leukemia in check longer
Disease control OngoingThis study tests whether adding a new targeted drug, pirtobrutinib, to standard therapy (venetoclax and rituximab) can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. About 600 participants will receive …
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 08:47 UTC
-
New hope for CLL patients: experimental drug LOXO-305 faces off against standard care
Disease control OngoingThis study compares a new oral drug, LOXO-305, to two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibito…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New pill challenges standard chemo for leukemia patients
Disease control OngoingThis study tests whether a daily pill called pirtobrutinib works better than the standard combination of bendamustine and rituximab for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants will be randomly as…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug shows promise in slowing rare thyroid cancer
Disease control OngoingThis study tests whether a new drug called selpercatinib works better than standard treatments for people with a rare type of thyroid cancer (medullary thyroid cancer) that has a specific gene change (RET mutation) and has spread or cannot be removed by surgery. About 291 adults …
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC